Cargando…

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease

Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs) in patients with sickle cell disease aged 16 yea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delgado, Julio, Voltz, Caroline, Stain, Milena, Lapveteläinen, Tuomo, Urach, Susanne, Lähteenvuo, Johanna, Penttilä, Karri, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240778/ https://www.ncbi.nlm.nih.gov/pubmed/34235401 http://dx.doi.org/10.1097/HS9.0000000000000604

Ejemplares similares

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

Ketamine for Sickle Cell Vaso-Occlusive Crises: A Systematic Review
por: Alshahrani, Mohammed S., et al.
Publicado: (2021)

A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease
por: Zaidi, Ahmar U., et al.
Publicado: (2021)

European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review
por: Dick, Maurice H, et al.
Publicado: (2022)

S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A, et al.
Publicado: (2022)

Vaso-occlusive crises in patients with sickle cell disease: Parents' perspectives and association with disease outcomes
por: Zolaly, Mohammed, et al.
Publicado: (2019)

Circulating Small Extracellular Vesicles May Contribute to Vaso-Occlusive Crises in Sickle Cell Disease
por: Gemel, Joanna, et al.
Publicado: (2022)

Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review
por: Akindele, Adebisi O, et al.
Publicado: (2022)

Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises
por: Soren, Uttam Kumar, et al.
Publicado: (2022)

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A. C., et al.
Publicado: (2022)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

PB2213: EFFECTIVENESS OF CRIZANLIZUMAB IN REDUCING VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE IN BRAZIL: STUDY PROTOCOL FOR AN OBSERVATIONAL, RETROSPECTIVE, MULTICENTER, NATIONAL STUDY
por: Bueno, C., et al.
Publicado: (2022)

The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive Crises
por: Ballas, Samir K.
Publicado: (2017)

Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
por: Udeze, Chuka, et al.
Publicado: (2023)

O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: A., SILVA-PINTO, et al.
Publicado: (2022)

Severe Painful Vaso-Occlusive Crises and Mortality in a Contemporary Adult Sickle Cell Anemia Cohort Study
por: Darbari, Deepika S., et al.
Publicado: (2013)

Score Predicting Acute Chest Syndrome During Vaso-occlusive Crises in Adult Sickle-cell Disease Patients
por: Bartolucci, Pablo, et al.
Publicado: (2016)

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study
por: Heeney, Matthew M., et al.
Publicado: (2022)

Correction to: Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States
por: Udeze, Chuka, et al.
Publicado: (2023)

PB2511: CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN GERMANY
por: Udeze, Chuka, et al.
Publicado: (2023)

Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study
por: Shah, Nirmish, et al.
Publicado: (2019)

Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease
por: Rab, Minke A. E., et al.
Publicado: (2020)

Shear-Stress-Gradient and Oxygen-Gradient Ektacytometry in Sickle Cell Patients at Steady State and during Vaso-Occlusive Crises
por: Boisson, Camille, et al.
Publicado: (2022)

P1447: MORTALITY AND CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN ITALY
por: Udeze, Chuka, et al.
Publicado: (2023)

Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report
por: Alshurafa, Awni, et al.
Publicado: (2022)

Whole blood transcriptomic analysis reveals PLSCR4 as a potential marker for vaso-occlusive crises in sickle cell disease
por: Abdulwahab, Hawra, et al.
Publicado: (2021)

The impact of Hydroxyurea on the rates of Vaso–occlusive crises in patients with sickle cell disease in Saudi Arabia: a single–center study
por: Alkhalifah, Sahar Abdullah, et al.
Publicado: (2022)

Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study
por: Kang, Hyeun Ah, et al.
Publicado: (2020)

The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease
por: Rizio, Avery A., et al.
Publicado: (2020)

Longitudinal assessment of adhesion to vascular cell adhesion molecule‐1 at steady state and during vaso‐occlusive crises in sickle cell disease
por: White, Jennell, et al.
Publicado: (2021)

Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials
por: Lowe, Michael, et al.
Publicado: (2023)

Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study
por: Kang, Hyeun Ah, et al.
Publicado: (2020)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

An Electronic Teaching Module for Improving Knowledge of Self-Management of Vaso-Occlusive Pain Crises in Patients With Sickle Cell Disease: Pilot Questionnaire Study
por: Tam, Tammie, et al.
Publicado: (2019)

The challenge of differentiating vaso-occlusive crises from osteomyelitis in children with sickle cell disease and bone pain: A 15-year retrospective review
por: Fontalis, A., et al.
Publicado: (2019)

Monocyte HLA-DR Expression to Monitor Immune Response and Potential Infection Risks Following Vaso-Occlusive Crises in Patients with Sickle Cell Anemia
por: Fort, Romain, et al.
Publicado: (2022)

Sickle cell vaso-occlusive crisis: it’s a gut feeling
por: Lim, Seah H., et al.
Publicado: (2016)

Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation of the Microvasculature the Trigger?
por: Veluswamy, Saranya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h0ro2tt009k5fjnqbobm9vquus